Dergiler / Experimed / 2023 / Cilt: 13 Sayı: 2

In vitro Antileishmanial Activity of Lavandula angustifolia Essential Oil on Leishmania infantum Parasites

Sayfa
115–120
Yayın Tarihi
2023-09-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The promising antileishmanial efficacy highlights the potential for further in vivo studies.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Leishmaniasis is an endemic tropical disease that is disseminated through the bite of a sandfly infected with Leishmania parasites.
📊
Temel Bulgular & Veri:This study investigated the antileishmanial effects of Lavandula angustifolia (LA) essential oil on Leishmania infantum (L. infantum) parasites, and the safety features were tested on RAW264.7 murine macrophages.
💡
Sonuç & Katkı:The promising antileishmanial efficacy highlights the potential for further in vivo studies.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Antileishmanial therapy · Lavandula angustifolia · Leishmania infantum

Abstract

Objective: Leishmaniasis is an endemic tropical disease that is disseminated through the bite of a sandfly infected with Leishmania parasites. Conventional antileishmanial drugs are mainly toxic and can be ineffective; therefore, there is a need for new natural drug candidates. This study investigated the antileishmanial effects of Lavandula angustifolia (LA) essential oil on Leishmania infantum (L. infantum) parasites, and the safety features were tested on RAW264.7 murine macrophages. Materials and Methods: LA essential oil was produced through the process of hydro-distillation, and its phytochemical content was determined using the gas chromatography-mass spectrometry (GC-MS) analysis. The antileishmanial effects of LA (0.063 to1 µL/mL) on L. infantum parasites as well as their safety features were assessed on RAW264.7 murine macrophages. Results: The composition of LA essential oil was detected using GC-MS analysis, including linalool, pinene, 1, 8-cineole, linalyl acetate, and lavandulol. Concentrations at and above 0.5 µL/mL LA indicated a significant reduction (71% decrease) in the parasite proliferation, and caused a slight reduction in macrophage viability to 70% at 72 h. Conclusions: The findings revealed the antileishmanial effect of LA on L. infantum parasites with relatively less toxicity on macrophages. The promising antileishmanial efficacy highlights the potential for further in vivo studies.

🔖

Bu Makaleye Atıf Yap

İŞLEK, Z., ŞAHİN, F. (2023). In vitro Antileishmanial Activity of Lavandula angustifolia Essential Oil on Leishmania infantum Parasites. Experimed, Cilt: 13 Sayı: 2, 115–120. https://ajindex.com/articles/962017

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Rodrigues V, Cordeiro-da-Silva A, Laforge M, Silvestre R, Estaquier J. Regulation of immunity during visceral Leishmania infection. Parasit Vectors 2016
  2. google scholar 2. Leishmaniasis. [cited 2023 23 May]. Available from https://www. who.int/news-room/fact- sheets/detail/leishmaniasis. google scholar 3. Sundar S, Chatterjee M. Visceral leishmaniasis - Current therapeutic modalities. Indian J Med Res 2006
  3. 123(3), 345-52. google scholar 4. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral Leishmaniasis. N Engl J Med 2002
  4. 347(22), 1739-46. google scholar 5. Shyam Sundar. 5 Journal Medicine. English J 2002
  5. 346(5): 305-10. google scholar 6. Köse Ş, Töz SÖ, Lu İCBĞ, Olut A, Korkmaz M, Özbel Y. Case Report: Treatment of Kala- Azar by Amphotericin B lipid complex ( ABELCET ® ). Türkiye Parazitoloji Dergisi 2004
  6. 28 (2): 126-8. google scholar 7. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005
  7. google scholar 8. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BPD, Nakamura CV. Recent advances in leishmaniasis treatment. Int J Infect Dis 2011
  8. 15(8): e525-e532. google scholar 9. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and treatment of leishmaniasis: Clinical practice guidelines by the infectious diseases society of America (IDSA) and the American Society of tropical medicine and hygiene (ASTMH). Am J Trop Med Hyg 2017
  9. 96(1): 24-45. google scholar 10. Gupta G, Oghumu S, Satoskar AR. Mechanisms of immune evasion in Leishmaniasis. In: Advances in applied microbiology. 2013. p. 155-84. google scholar 11. Sahar H. Al-Natour. Update in the treatment of cutaneous Leishmaniasis. J Fam Community 2009
  10. 16(2): 41-7. google scholar 12. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist 2012
  11. google scholar 13. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: A multicenter study. Clin Infect Dis 2003
  12. 37(6): 800-4. google scholar 14. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: Drugs in the clinic, resistance and new developments. Drug Resist Updat 2004
  13. 7(4-5): 257-66. google scholar 15. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Mic